The Latest Breaking News from ALBO

Rockstars & Politicians Are Weighing In On Albo’s Alleged $50B AI Deal: ‘A Violation’

The $50B deal could see copyright extentions granted for AI training.

Pedestrian.tv · Jul 3

‘Albo said how much he loved them’: bespoke beers just the thing for an Australian prime minister’s wedding

Creating customised cans for Anthony Albanese and Jodie Haydon’s big day was a first for Sydney’s Willie the Boatman brewery. But personalised nuptial drinks are a growing trend

The Guardian - AU · Dec 1, 2025

Anthony Albanese Dragged For Controversial Meme About The Cost Of Living Crisis: ‘Infantile’

PM Anthony Albanese's attempt at a meme about the cost of living crisis has backfired spectacularly. Here are all the cringe filled details.

Pedestrian.tv · Aug 8, 2024

Stakes are lower than you think on Voice vote if you're not Indigenous

'This is a straightforward, modest and long-overdue proposition'.

Newcastle Herald · Sep 10, 2023

Albo's steak dinner has gone fancy

The lunch at the National Press Club had a special Albanese flavour

The Canberra Times · May 18, 2022

Albireo Pharma: Q1 Earnings Insights

Albireo Pharma (NASDAQ:ALBO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Albireo Pharma missed estimated earnings by 18.38%, reporting an EPS of $-2.19 versus an estimate of $-1.85.

Benzinga · May 16, 2022

Albireo Pharma's Earnings Outlook

Albireo Pharma (NASDAQ:ALBO) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Albireo Pharma will report an earnings per share (EPS) of $-1.85.

Benzinga · May 13, 2022

ELECTION RECAP: Scooter Kicks Off His Campaign With Transphobia, Beer & Stupid Smirks

"Zoom in mate."

Pedestrian.tv · Apr 11, 2022

Our PM's very good at pointing the finger

Newcastle Herald readers have their say

Newcastle Herald · Apr 6, 2022

Albireo Pharma Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Albireo Pharma (NASDAQ:ALBO) reported Q4 sales of $32.52 million. Earnings fell to a loss of $10.96 million, resulting in a 119.2% decrease from last quarter.

Benzinga · Mar 3, 2022